Anti-Hu-associated paraneoplastic sensory neuronopathy responding to early aggressive immunotherapy: Report of two cases and review of literature

Oh, Shin J.; Dropcho, Edward J.; Claussen, Gwen C.

doi:10.1002/(sici)1097-4598(199712)20:12<1576::aid-mus13>3.0.co;2-z

Cited by 70 publications

(33 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…25 Patients with electrophysiological features of demyelination have also been reported. 26 Our results suggest that patients with anti-Hu antibodies and slow conduction velocities should be screened for the presence of anti-CV2 antibodies.…”

Section: Discussionmentioning

confidence: 72%

Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy

Antoine¹,

et al. 2001

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 72%

Paraneoplastic anti-CV2 antibodies react with peripheral nerve and are associated with a mixed axonal and demyelinating peripheral neuropathy

Antoine¹,

et al. 2001

View full text Add to dashboard Cite

“…According to one study, patients harbouring antiHu antibodies seem to respond particularly well to oncological treatment [9]. Treatment of the tumour may also improve the neuropathic symptoms in some patients [13,21]. Considering the often very severe nature of the neuropathy, this is certainly another argument favouring an aggressive approach to investigations.…”

Section: Discussionmentioning

confidence: 99%

Neuropathy and malignancy: a retrospective survey

Storstein¹,

Vedeler²

2001

Journal of Neurology

View full text Add to dashboard Cite

Peripheral neuropathy is a common condition with a variety of causes. In some cases the neuropathy is the first symptom of an underlying malignancy. The frequency of occult cancer in patients with neuropathy is of importance in planning the investigations and follow-up of these patients. This retrospective study examined the incidence of cancer-related neuropathy among patients originally diagnosed with idiopathic peripheral neuropathy. Between 1981-1995 our department discharged 187 patients with the diagnosis of idiopathic peripheral neuropathy. Their names were cross-matched with the Norwegian Cancer Registry, and the medical records of the patients with known cancer were reviewed. In 14 patients (7.5%) we found cancer as the probable cause of the peripheral neuropathy originally classified as idiopathic. In eight of the patients the neuropathic symptoms preceded the tumour. In six cancer was already diagnosed when the neuropathic symptoms developed, but in three of these the neuropathy heralded a tumour recurrence. Idiopathic progressive neuropathy should always raise the suspicion of an underlying malignancy, especially if there are atypical accompanying symptoms and signs.

show abstract

“…27 Improvement of peripheral anti-Hu manifestations with early aggressive immunotherapy has been reported in other cases. 19,30 Perhaps the irreversible neuronal loss that occurs in anti-Hu syndrome 5,6,28 was not extensive enough in our case, or the marked reduction in anti-Hu antibody titer early in the course (Table 3) spared our patient from further damage. Another explanation for the resolution of anti-Hu manifestations derives from the observation that anti-Hu antibodies can be found in neurons that appear histologically normal.…”

Section: Discussionmentioning

confidence: 67%